This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients. The eligible patient will be assigned to study treatment with Quetiapine XR on Day 1. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
96
oral, once daily, flexible dose
Research site
Ansan, Gyeonggi-do, South Korea
Research site
Gwangju, Gyeonggi-do, South Korea
Research site
Bugok, Gyeongsangnam-do, South Korea
Research site
Masan, Gyeongsangnam-do, South Korea
The Change in Positive and Negative Syndrome Scale(PANSS)Total Score
PANSS, a 30-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme), total score is 30 - 210. Description of the reporting Groups: Evaluate the efficacy of Quetiapine XR with daily dose 400 mg - 800 mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline to Day 57 in total score of PANSS using the last observation carried forward (LOCF) method
Time frame: From baseline to Day 57
Positive and Negative Syndrome Scale (PANSS) Positive Score
To evaluate the change of positive symptoms from baseline to Day 57 in PANSS positive score, a 7-item scale where eash symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)
Time frame: From baseline to Day 57
Positive and Negative Syndrome Scale (PANSS) Negative Score
To evaluate the change of negative symptoms from baseline to Day 57 in PANSS negative score, a 7-item scale where each symptom is rated on a severity scale ranging from 1 (absent) - 7 (extreme)
Time frame: From baseline to Day 57
Positive and Negative Syndrome Scale (PANSS) General Psychopathology Score
To evaluate the change of general psychopathology symptoms from baseline to Day 57 in PANSS general score, a 16-item scale where each symptom is rated on a severity scale ranging from 1 (absent) to - 7 (extreme)
Time frame: From baseline to Day 57
Clinical Global Impression (CGI) Score
The Clinical Global Impression - Severity (CGI-S) and - illness (CGI-I) is used in this study. The CGI-S is scored to rate the patient's current clinical state. The CGI-I is scored to rate the patient's change from baseline CGI. Each CGI item is scored on a scale from 1 to 7 (CGI-S: 1 = Normal, not ill, 7= Among the most extremely ill patients/ CGI-I: 1= very much improved, 7= very much worse). CGI-I scores greater than 4 indicate worsening, while scores less than 4 indicate improvement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research site
Incheon, South Korea
Research site
Pusan, South Korea
Research site
Seoul, South Korea
Time frame: From baseline to Day 57
Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
To treat depressive symptoms in acute schizophrenic patients by evaluation of the change from baseline to day 67 in MADRS total score, a 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0-6 scale, higher MADRS scores indicate higher levels of depressive symptoms.
Time frame: From baseline to Day 57
Global Assessment of Functioning (GAF) Score
To improve functional capability in acute schizophrenic patients by evaluation of the change from baseline to Day 57 in GAF scale score, a single-item rating scale for evaluating the overall functioning on a continuum from psychologic or psychiatric sickness to health.
Time frame: From baseline to Day 57